Bioventix PLC Stock

Equities

BVXP

GB00B4QVDF07

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:15 2024-05-13 am EDT 5-day change 1st Jan Change
4,375 GBX 0.00% Intraday chart for Bioventix PLC +1.16% +1.74%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 14M 17.58M Sales 2025 * 15.1M 18.96M Capitalization 228M 287M
Net income 2024 * 8M 10.04M Net income 2025 * 9M 11.3M EV / Sales 2024 * 15.9 x
Net cash position 2024 * 6M 7.53M Net cash position 2025 * 6.4M 8.04M EV / Sales 2025 * 14.7 x
P/E ratio 2024 *
26.6 x
P/E ratio 2025 *
24.6 x
Employees 12
Yield 2024 *
3.68%
Yield 2025 *
3.93%
Free-Float 91.92%
More Fundamentals * Assessed data
Dynamic Chart
1 week+1.16%
Current month+2.34%
1 month-4.89%
3 months-7.89%
6 months+23.24%
Current year+1.74%
More quotes
1 week
4 250.00
Extreme 4250
4 450.00
1 month
4 210.00
Extreme 4210
4 700.00
Current year
4 179.00
Extreme 4179
5 100.00
1 year
3 402.00
Extreme 3402
5 100.00
3 years
2 880.00
Extreme 2880
5 100.00
5 years
2 590.00
Extreme 2590
5 100.00
10 years
26.51
Extreme 26.51
5 100.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 03-12-22
Director of Finance/CFO 65 20-06-30
Members of the board TitleAgeSince
Chairman 64 04-04-25
Chief Executive Officer 65 03-12-22
Director/Board Member 71 14-01-24
More insiders
Date Price Change Volume
24-05-13 4,375 0.00% 19,803
24-05-10 4,375 +0.57% 4,223
24-05-09 4,350 +1.16% 4,297
24-05-08 4,300 -0.58% 6,642

Delayed Quote London S.E., May 13, 2024 at 11:35 am EDT

More quotes
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Calendar
More about the company

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW